Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in select solid tumors.
Advanced Solid Tumors|MSI-H/dMMR Tumors|Cutaneous Squamous Cell Carcinoma|Urothelial Carcinoma, HCC|Cervical Cancer|Esophageal Squamous Cell Carcinoma|Merkel Cell Carcinoma|Small-cell Lung Cancer|Mesothelioma|PD-L1 Amplified Tumor (9p24.1)|Nasopharyngeal Carcinoma|Cyclin-dependent Kinase 12 Mutated Tumors|Basal Cell Carcinoma (Unresectable or Metastatic)|Sarcomatoid Renal Cell Carcinoma|Clear Cell Ovarian or Endometrial Carcinoma|Anal Carcinoma|Squamous Cell Penile Carcinoma|DNA Polymerase Epsilon Mutated Tumors (P286R and V411L)
DRUG: INCB099318
Number of treatment-emergent adverse events, Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug up to 30 days after last dose of study drug., Up to approximately 25 months
Cmax of INCB099318, Maximum observed plasma concentration, Up to approximately 3 months|tmax of INCB099318, Time to maximum plasma concentration, Up to approximately 3 months|Cmin of INCB099318, Minimum observed plasma concentration over the dose interval, Up to approximately 3 months|AUC0-t of INCB099318, Area under the plasma concentration-time curve from time = 0 to the last measurable concentration at time = t, Up to approximately 3 months|t½ of INCB099318, Apparent terminal-phase disposition half-life, Up to approximately 3 months|λz of INCB099318, Terminal elimination rate constant, Up to approximately 3 months|CL/F of INCB099318, Oral dose clearance, Up to approximately 3 months|Vz/F of INCB099318, Apparent oral dose volume of distribution, Up to approximately 3 months
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in select solid tumors.